[(2,4-dinitrophenyl)sulfonyl]glycine ethyl ester | 392330-57-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2,4-dinitrophenyl)sulfonyl]glycine ethyl ester
• 英文别名: ethyl N-[(2,4-dinitrophenyl)sulfonyl]glycinate；ethyl N-(2,4-dinitrophenylsulfonyl)glycinate；2,4-Dinitrobenzenesulfonyl glycine ethyl ester；ethyl 2-[(2,4-dinitrophenyl)sulfonylamino]acetate
• CAS: 392330-57-3
• 化学式: C₁₀H₁₁N₃O₈S
• 分子量: 333.279
• InChiKey: WMFYLDAIFWWJIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  173
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  [(2,4-dinitrophenyl)sulfonyl]glycine ethyl ester 、 Boc-Lys(guanidine-di-Cbz)-ol 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 以76%的产率得到Boc-Lys{(guanidine-di-Cbz)-ψ[CH2N(o,p-diNBS)]}Gly-OEt
  参考文献：
  名称：

  Synthesis of Conformationally Preorganized and Cell-Permeable Guanidine-Based γ-Peptide Nucleic Acids (γGPNAs)

  摘要：

  A general method for preparing optically pure guanidine-based gamma-peptide nucleic acid (gamma GPNA) monomers for all four natural nucleobases (A, C, G, and T) is described. These second-generation gamma GPNAs differ from the first-generation GPNAs in that the guanidinium group is installed at the gamma- instead of the alpha-position of the N-(2-aminoethyl)glycine backbone unit. This positional switch enables GPNAs to be synthesized from relatively cheap L- as opposed to D-amino acids. Unlike their (x-predecessors, which are randomly folded, gamma GPNAs prepared from L-amino acids are preorganized into a right-handed helix and bind to DNA and RNA with exceptionally high affinity and sequence selectivity and are readily taken up by mammalian cells.

  DOI：

  10.1021/jo802211n
• 作为产物：
  描述：

  2,4-二硝基苯磺酰氯 、 2-胺基乙酸乙酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 [(2,4-dinitrophenyl)sulfonyl]glycine ethyl ester
  参考文献：
  名称：

  磺酰基烷基酰胺的发现：新型的口服活性因子Xa抑制剂。

  摘要：

  Xa因子（FXa）是一种参与凝血级联反应的胰蛋白酶样丝氨酸蛋白酶，作为开发新型抗血栓药的潜在靶标已引起广泛关注。已发现大多数报道的am型FXa抑制剂显示出极差的口服生物利用度。化合物1是最早报道的非-型FXa抑制剂之一。为了发现新颖的口服活性FXa抑制剂，我们研究了6-氯萘环与1的1-（吡啶-4-基）哌啶部分之间的柔性线性接头，发现口服活性的磺酰基烷基酰胺2f与FXa IC（50）相同。 0.05 microM，与1相当。进一步的修饰以降低2f的CYP3A4抑制活性导致产生有力，选择性和口服活性的2-甲基吡啶类似物2s（FXa IC（50）为0.061 microM），CYP3A4抑制作用比2f显着减弱。化合物2s在食蟹猴中也显示出持久的抗凝活性。

  DOI：

  10.1016/j.bmc.2007.11.073

文献信息

• Sulfone derivatives, process for their production and use thereof
  申请人：——

  公开号：US20030187023A1

  公开（公告）日：2003-10-02

  A compound represented by the formula: 1 wherein R is a cyclic hydrocarbon group, or the like; W is a bond, or the like; X is a divalent hydrocarbon group, or the like; Y and Z are each independently —N(R 6 )— or the like; ring A is a nitrogen-containing heterocyclic ring, or the like; R5 and R6 are independently hydrogen atom, a hydrocarbon group, or the like; Z′ is imidoyl group, or the like; a is 0, 1 or 2; and b is 0 or 1, or a salt thereof.

  一个由以下式表示的化合物： 其中R是一个环烃基团，或类似物；W是一个键，或类似物；X是一个二价碳氢基团，或类似物；Y和Z分别独立地为—N(R6)—或类似物；环A是一个含氮杂环环，或类似物；R5和R6独立地为氢原子、一个碳氢基团，或类似物；Z′是亚胺基团，或类似物；a为0、1或2；b为0或1，或其盐。
• SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1302462A1

  公开（公告）日：2003-04-16

  A compound represented by the formula: wherein R is a cyclic hydrocarbon group, or the like; W is a bond, or the like; X is a divalent hydrocarbon group, or the like; Y and Z are each independently -N(R6)- or the like; ring A is a nitrogen-containing heterocyclic ring, or the like; R5 and R6 are independently hydrogen atom, a hydrocarbon group, or the like; Z' is imidoyl group, or the like; a is 0, 1 or 2; and b is 0 or 1, or a salt thereof.

  一种由式表示的化合物： 其中 R 是环状烃基，或类似物；W 是键，或类似物；X 是二价烃基，或类似物；Y 和 Z 各自独立地是 -N(R6)- 或类似物；环 A 是含氮杂环，或类似物；R5 和 R6 独立地是氢原子、烃基，或类似物；Z'是咪唑酰基，或类似物；a 是 0、1 或 2；b 是 0 或 1，或其盐。
• Synthesis and Characterization of Conformationally Preorganized, (<i>R</i>)-Diethylene Glycol-Containing γ-Peptide Nucleic Acids with Superior Hybridization Properties and Water Solubility
  作者：Bichismita Sahu、Iulia Sacui、Srinivas Rapireddy、Kimberly J. Zanotti、Raman Bahal、Bruce A. Armitage、Danith H. Ly

  DOI：10.1021/jo200482d

  日期：2011.7.15

  Developed in the early 1990s, peptide nucleic acid (PNA) has emerged as a promising class of nucleic acid mimic because of its strong binding affinity and sequence selectivity toward DNA and RNA and resistance to enzymatic degradation by proteases and nucleases; however, the main drawbacks, as compared to other classes of oligonucleotides, are water solubility and biocompatibility. Herein we show that installation of a relatively small, hydrophilic (R)-diethylene glycol ("miniPEG", R-MP) unit at the gamma-backbone transforms a randomly folded PNA into a right-handed helix. Synthesis of optically pure (R-MP)gamma PNA monomers is described, which can be accomplished in a few simple steps from a commercially available and relatively cheap Boc-L-serine. Once synthesized, (R-MP)gamma PNA oligomers are preorganized into a right-handed helix, hybridize to DNA and RNA with greater affinity and sequence selectivity, and are more water soluble and less aggregating than the parental PNA oligomers. The results presented herein have important implications for the future design and application of PNA in biology, biotechnology, and medicine, as well as in other disciplines, including drug discovery and molecular engineering.
• [EN] TELOMERASE INHIBITOR<br/>[FR] INHIBITEUR DE TELOMERASE
  申请人：GERON CORP

  公开号：WO2002053155A1

  公开（公告）日：2002-07-11

  The present invention provides a telomerase inhibitor containing as an active ingredient a compound which has the 4-oxo-2-thioxoimidazolidine skeleton and which has telomerase inhibitory activity.
• Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors
  作者：Yasuhiro Imaeda、Toshio Miyawaki、Hiroki Sakamoto、Fumio Itoh、Noriko Konishi、Katsuhiko Hiroe、Masaki Kawamura、Toshimasa Tanaka、Keiji Kubo

  DOI：10.1016/j.bmc.2007.11.073

  日期：2008.3

  cascade and has received great interest as a potential target for the development of new antithrombotic agents. Most of amidine-type FXa inhibitors reported have been found to show extremely poor oral bioavailability. Compound 1 is one of the first reported non-amidine type FXa inhibitors. To discover novel and orally active FXa inhibitors, we investigated flexible linear linkers between the 6-chloronaphthalene

  Xa因子（FXa）是一种参与凝血级联反应的胰蛋白酶样丝氨酸蛋白酶，作为开发新型抗血栓药的潜在靶标已引起广泛关注。已发现大多数报道的am型FXa抑制剂显示出极差的口服生物利用度。化合物1是最早报道的非-型FXa抑制剂之一。为了发现新颖的口服活性FXa抑制剂，我们研究了6-氯萘环与1的1-（吡啶-4-基）哌啶部分之间的柔性线性接头，发现口服活性的磺酰基烷基酰胺2f与FXa IC（50）相同。 0.05 microM，与1相当。进一步的修饰以降低2f的CYP3A4抑制活性导致产生有力，选择性和口服活性的2-甲基吡啶类似物2s（FXa IC（50）为0.061 microM），CYP3A4抑制作用比2f显着减弱。化合物2s在食蟹猴中也显示出持久的抗凝活性。